The strategic agreement brings the US company’s mobile hearing and tinnitus platform to the Japanese consumer market.
US-based digital health company AudioCardio has entered a strategic partnership with Taisho Pharmaceutical Co Ltd, to launch its hearing and tinnitus management app in Japan. Under the agreement, Taisho will oversee the localization, strategy, and commercialization of the AudioCardio app for the Japanese market.
The smartphone-based platform is designed to help individuals manage their hearing and tinnitus through personalized assessments, adaptive sound experiences, and progress tracking. The app will be available to Japanese users through the Apple App and Google Play stores. For the Japanese market, the AudioCardio app is positioned as a healthcare application and is not regulated as a Software as a Medical Device (SaMD).
For AudioCardio, the partnership provides entry into a key global healthcare market.
“Japan is a global leader in healthcare quality and innovation, and also one of the most impacted by hearing loss and tinnitus,” says Chris Ellis, founder and CEO of AudioCardio, in a release. “Partnering with Taisho provides unmatched credibility, scale, and local expertise. This launch is not just market entry; it is a platform for long-term growth and deeper collaboration.”
The launch represents an initial step in a broader strategic vision for both companies, which see potential to expand their collaboration as digital healthcare continues to evolve.
